TargImmune
Elisabethenstrasse 43
Basel
4051
About TargImmune
TargImmune Therapeutics is a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies. The company's principal technology is the CTPIC technology platform that utilizes a proprietary non-viral vector to target and destroy cancer cells that over-express certain receptors.YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Dr. Esteban Pombo-Villar
Chairman of the Board: Dr. Peter Kash
3 articles about TargImmune
-
TargImmune Announces Successful Completion of GLP/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development
6/7/2022
TargImmune Therapeutics AG announced two major milestones - the appointment of Dr Marc Thommen as Head of Technical Development, and the successful completion of GLP/Tox studies.
-
TargImmune Announces Another Senior Hire as Veronica Hersberger Revealed As New Chief Medical Officer
2/7/2022
TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, announced the further expansion of their management team with the appointment of Veronica Hersberger as Chief Medical Officer.
-
Race Joint Venture With TargImmune
7/10/2017